AI Eye Health Application
DIAGNOS Submits Updated Health Canada Licence Application for AI-Powered CARA System
Anonymous
DIAGNOS Inc. has filed a modified and updated application with Health Canada for a Class II medical device licence covering its CARA AI eye-screening platform, the company announced June 16, 2026. The filing caps nearly two years of regulatory back-and-forth and follows specific guidance Health Canada issued in fall 2025 on how to regulate AI-powered medical software. The Province reported the submission marks a major step toward full commercial launch in Canada.
The CARA system uses artificial intelligence to help optometrists detect conditions like diabetic retinopathy — the leading cause of blindness in adults aged 20 to 74 — through retinal photography. The platform has already assessed more than 400,000 patients across 140 clinics in 16 countries, according to company data cited by Edmonton Sun.
Two Years of Regulatory Hurdles Finally Cleared
DIAGNOS first submitted its Health Canada application in early September 2024. After 11 proactive follow-up inquiries from the company, the agency confirmed in April 2025 that the file had moved from a backlog into "active processing." Health Canada then issued detailed guidance in fall 2025, requiring DIAGNOS to redesign key parts of the application to meet new rules for AI-enabled medical devices, according to Ottawa Sun.
The new rules, which took effect February 2, 2026, require companies to file digitally through Health Canada's Common Electronic Submission Gateway. They also demand a Predetermined Change Control Plan — essentially a roadmap for how the AI model can be updated after approval. DIAGNOS CEO André Larente said the team focused on "rigor and discipline" to meet those standards.
CARA Platform Targets Canada's Diabetes Blindness Crisis
The CARA system is not a single tool — it is a full Picture Archiving and Communications System with four modules. CARA-Enhancement sharpens retinal images. CARA-AM Detect spots age-related macular degeneration. CARA-DR flags diabetic retinopathy. CARA-MVA detects macular vascular abnormalities. Results come back within minutes, which the company says will boost patient compliance for diabetic eye screenings — currently a major gap in Canadian healthcare, according to Stratford Beacon Herald.
Dr. Ike Ahmed, Medical Director at Prism Eye Institute, has publicly backed the platform. He said it enables "earlier intervention, better care, and massive savings to the system." Labtician Ophthalmics, DIAGNOS's exclusive Canadian distributor, is already positioned to roll the system out to optical chains including EssilorLuxottica and IRIS once approval is granted.
Approval Could Unlock U.S. and Saudi Markets Too
A Canadian licence would carry weight well beyond the country's borders. DIAGNOS is running parallel regulatory processes with the U.S. FDA — where it completed a pre-submission review with advisor ORA LLC in July 2025 — and with the Saudi Food and Drug Authority. Analysts at Emerging Growth Research called the June 16 filing a "regulatory catalyst" that could unlock a multi-billion dollar global market, according to Whitecourt Star.
The same analysts noted that DIAGNOS followed Health Canada's new frameworks closely, which lowers the risk of receiving a Screening Deficiency Notice — a common setback for AI startups navigating the updated rules. In February 2026, the company also secured C$1.0 million in federal funding for next-generation retinal AI algorithms, giving it additional runway during the review period.
A Small Company With a Lot Riding on This Decision
DIAGNOS carries a market capitalization of just $18.4 million as of early June 2026. Its stock traded between $0.14 and $0.15 per share in the days before the announcement. With trailing twelve-month revenue of only $48,700 and a negative earnings per share of -$0.04, the company is burning cash. Regulatory approval is not just a milestone — for investors, it is a financial lifeline, according to Brantford Expositor.
Health Canada typically aims to decide on Class II device applications within 15 to 90 days, though AI-enabled devices can face longer technical screening. Larente has said securing the licence is "a priority milestone" that the company believes will serve as "a significant catalyst for commercial growth." The clock is now running.
Sentiment
NeutralNEGATIVENEUTRALPOSITIVE
Publishers
15
Articles
15
Reach
15
A
AnonymousAuthor
